In Part 1 of a two-part interview, University of Toronto's Roger McIntyre discusses treatment-resistant depression, why many antidepressants fall short, and the growing promise of ketamine. Then, Ozempic for depression? The latest on GLP-1s and mental health.
See omnystudio.com/listener for privacy information.